Steve Harr, Sana CEO
Game change: A frontrunner in the cell therapy 2.0 field offers a first look at their lead therapy. And it’s a doozy
When a pair of CAR-T pioneers from Juno launched Sana Biotechnology back at the beginning of 2019, they had some grand and rather vaguely …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
